Clinical Trial Update: A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence [Phase 3]

View source ↗

Summary

The document reports a long-term extension of a Phase 3 study evaluating nalmefene for alcohol dependence, with completed status and results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Dependence

Drugs mentioned

• Nalmefene (nalmefene)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Alcohol Dependence | Phase 3 | Status: COMPLETED | Results posted: 2020-07-20